COVID-19: Centre Waives Import Duty on Remdesivir and Its Raw Materials
PTI
Real journalism holds power accountable
Since 2015, The Wire has done just that.
But we can continue only with your support.
New Delhi: Amid surging COVID-19 cases in the country, the government on Tuesday waived customs duty on Remdesivir, its raw materials and other components used to make the antiviral drug.
The move would help augment domestic availability and reduce cost of the injection.
Remdesivir is being used in the treatment of coronavirus.
In a notification, the Department of Revenue said "the central government, on being satisfied that it is necessary in the public interest to do, hereby exempts the goods...when imported into India, from the whole of the duty of customs leviable".
The items on which the duty has been waived include Remdesivir active pharmaceutical ingredients (APIs), injection Remdesivir, and beta Cyclodextrin used in manufacture of Remdesivir.
This import duty exemption would remain in force till October 31st this year.
Commerce and Industry Minister Piyush Goyal tweeted, "In line with PM @NarendraModi's priority to ensure affordable medical care for COVID-19 patients, imports of Remdesivir API, injection and specific inputs have been made import duty free. This should increase supply and reduce cost thus providing relief to patients."
Earlier on April 11, in view of increased demand for Remdesivir, the Centre banned export of the injection and its APIs till the situation improves.
Also read: White House Evasive on Lifting Ban on COVID-19 Vaccine Raw Materials Export to India
The National Pharmaceutical Pricing Authority (NPPA) had last week said various drug companies had cut the prices of Remdesivir injection on the intervention of the government.
Cadila Healthcare has reduced the price of its REMDAC (Remdesivir 100 mg) injection from Rs 2,800 to Rs 899.
Similarly, Syngene International has cut the price of its brand RemWin from Rs 3,950 to Rs 2,450.
Hyderabad-based Dr Reddy's Laboratories has cut the price of REDYX from Rs 5,400 to Rs 2,700 now. Similarly, Cipla has reduced the price of its CIPREMI brand from Rs 4,000 to Rs 3,000.
Mylan has also reduced the price of its brand from Rs 4,800 to Rs 3,400. Similarly, Jubilant Generics has cut the price of its Remdesivir brand from Rs 4,700 earlier to Rs 3,400.
Hetero Healthcare has cut the price of its brand COVIFOR from Rs 5,400 to Rs 3,490.
This article went live on April twenty-first, two thousand twenty one, at twenty-four minutes past one in the afternoon.The Wire is now on WhatsApp. Follow our channel for sharp analysis and opinions on the latest developments.